source
- U.S. proposes rule tightening review of biotech licensing deals with Chinese firmsThe U.S. is preparing to issue a proposed rule that would place additional scrutiny on outbound licensing agreements between American biotech firms and Chinese companies. The measure aims to increa…
- FDA accepts new submission for Biohaven’s Vyglxia, opening path to approvalBiohaven announced that the FDA has accepted a refreshed application for its rare disease drug Vyglxia, which targets a nerve‑damaging disorder. Vyglxia is being developed for spinocerebellar atax…